Abstract
Parkinson’s disease is one of the commonest neurological conditions in Great Britain and in America but its incidence and prevalence have been little studied. Incidence rates, which measure the number of new cases per unit population per year, are useful for acute onset conditions, but misleading for diseases of insidious onset as many early cases can be missed. Prevalence rates, which measure the number of cases per unit population on a given date, are more useful for more chronic conditions such as Parkinson’s disease. In 1952 Garland1 found a prevalence rate of 59 cases per 100 000 of the general population in the Leeds area, a rate which he regarded as approximate and minimal. Brewis et al. in 19662 reported an overall prevalence rate of 112·5 per 100 000 in the Carlisle population of 1961, and showed the rates for different age groups. They believed that Parkinsonism was underdiagnosed and therefore that their figure was an underestimate. An American study by Kurland in 1958 in Rochester3 showed a greater prevalence than that at Carlisle for each age group, and the overall prevalence rate was 187 per 100 000. They believed that their survey, using the facilities of the Mayo clinic, was far more complete than previous ones.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Garland, H. G. (1952). Parkinsonism. Br. Med. J, 1, 153
Brewis, M., Poskanzer, D. C., Rolland, C. and Miller, H. (1962). Neurological disease in an English city. Acta Neurol. Scand, 24 (Suppl.) 42, 31
Kurland, L. T. (1958). In: W. S. Fields (ed.). Pathogenesis and Treatment of Parkinsonism, p5. (Springfield, 111.: Charles C. Thomas )
Gudmundsson, K. R. (1967). A clinical survey of Parkinsonism in Iceland. Acta Neurol. Scand, 33 (Suppl), 43,
Parkinson’s Disease (1974). Studies of Current Health Problems No. 51. ( London: Office of Health Economics )
Hoehn, M. M. and Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology, 17, 427
Harris, A. I. (1971). Handicapped and Impaired in Great Britain ( London: HMSO )
Sweet, R. D. and McDowell, F. H. (1975). Five years treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann. Intern. Med, 83, 456
Rinne, U. K. (1978). Recent advances in research on Parkinsonism. Acta Neurol Scand, 67 (Suppl.) 57, 77
Critchley, M. (1929). Arteriosclerotic Parkinsonism. Brain, 52, 23
Parkes, J. D., Marsden, C. D., Rees, J. E., Curzon, G., Katamaneni, B. D., Knill-Jones, R., Akbar, A., Das, S., and Kataria, M. (1974). Parkinson’s disease, cerebral arteriosclerosis and senile dementia. Q. J. Med, 43, 49
Locket, S. (1957). Clinical Toxicology. ( London: Kimpton )
Smith, J. S., and Brandon, S. (1970). Acute carbon monoxide poisoning - three years’ experience in a defined population. Postgrad. Med. J, 46, 65
Parkinson, J. (1817). An Essay on the Shaking Palsy. (London: Sherwood, Neely and Jones )
Nowack, W. J., Hatelid, J. M. and Sohn, R. S. (1977). Dysphagia in Parkinsonism. Arch. Neurol, 34, 320
Logemann, J. A., Blonsky, E. R. and Boshes, B. (1970). Dysphagia in Parkinsonism. J. Am. Med. Assoc 231, 69
Webster, D. D. (1968). Critical analysis of the disability in Parkinson’s disease. Mod. Treatment, 5, 257
Mehta, A. D., Wright, W. B. and Kirby, B. J. (1978). Ventilatory function in Parkinson’s Disease. Br. Med. J, 1, 1456
Wartenberg, R. (1952). Head-dropping test. Br. Med. J, 1, 687
Hildick-Smith, M. (1976). Assessing dementia in the older Parkinsonian patient. Mod. Geriatr, 6, 33
Hodkinson, H. M. (1972). Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing, 1, 233
Greenfield, J. G. and Bosanquet, F. D. (1953). The brainstem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatry, 16, 213
Pearce, J. M. S. (1978). Aetiology and natural history of Parkinson’s disease. Br. Med. J, 4, 1664
Ehringer, H. and Hornykiewicz, O. (1960). Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr, 38, 1236
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. and Seiteiberger (1965). Zur Differenzierung des Parkinson - Syndroms. Proceedings of 8th Inter-national Congress of Neurology, p. 145 ( Vienna: Medical Academy )
Birkmayer, W. and Hornykiewicz, O. (1961). Der L-3, 4 dioxyphenylalanin (= DOPA) Effekt bei der Parkinsonakinese. Wien. Klin. Wochenschr, 73, 787
Barbeau, A., Sourkes, T. L. and Murphy, G. F. (1962). Les catecholamines dans la maladie de Parkinsonism. In J. de Ajuriaguerra (ed). Monoamines et Système Nerveux Centrale, p. 247. ( Paris: Masson )
Rinne, U. K., Riekkinen, P., Sonninen, V. and Laaksonen, H. (1973). Brain acetylcholinesterase in Parkinson’s disease. Acta Neurol. Scand, 49, 215
Bowen, D. M. and Davison, A. N. (1978). Biochemical changes in the normal ageing brain. In B. Isaacs (ed). Recent Advances in Geriatric Medicine, p. 54. ( Edinburgh, London and New York: Churchill Livingstone )
Lewis, C., Ballinger, B. R. and Presly, A. S. (1978). Trial of levodopa in senile dementia. Br. Med. J, 1, 550
Birkmayer, W., Ambrozi, L., Neumayer, E. and Riederer, P., (1974). Longevity in Parkinson’s disease treated with L-dopa. Clin. Neurol Neurosurg, 1, 15
Duvoisin, R. C. (1969), In Crane, G. E. and Gardiner, R. Jr. (eds.). Psychotropic Drugs and Dysfunction of Basal Ganglia, p. 134 ( Washington: US Public Health Services )
Hughes, R. C., Polgar, J. G., Weightman, D. and Walton, J. N. (1971), L-dopa in Parkinsonism - the effects of withdrawal of anticholinergic drugs. Br. Med. J, 2, 487
Broe, G. A. and Caird, F. I. (1973). Levodopa for Parkinsonism in elderly and demented patients. Med. J. Aust, 1, 630
Caird, F. I. (1974). Parkinsonism. In Anderson W. F. and Judge T. C. (eds.). Geriatric Medicine, pp. 171–183 ( London and New York: Academic Press )
Caird, F. I. and Williamson J. (1978). Drugs for Parkinson’s disease. Lancet, i, 986
Mindham, R. H., Lamb, P. and Bradley, R. (1977). A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced Parkinsonism. Br. J. Psychiatry 130, 581
Schwab, R. S., England, A. C., Poskanzer, D. C. and Young, R. R. (1969). Amantadine in the treatment of Parkinson’s disease. J. Am. Med. Assoc, 208, 1168
Cotzias, G. C., van Woert, M. H. and Schiffer, L. M. (1967). Aromatic amino- acids and modification of Parkinsonism. N. Engl. J. Med, 276, 374
Calne, D. B., Spiers, A. S., Stern, G. M., Lawrence, D. R. and Armitage, P. (1969). L-dopa in idiopathic Parkinsonism. Lancet, ii, 973
Godwin-Austen, R. B., Tomlinson, E. B., Frears, C. C. and Kok, H. W. L. (1969). Effects of L-dopa in Parkinson’s disease. Lancet, ii, 165
Yahr, M. D., Duvoisin, R. C., Hoehn, M. M., Schear, M. and Barrett, R. E. (1968). L-dopa, its clinical effects in Parkinsonism. Trans. Am. Neurol. Assoc, 93, 56
Mawdsley, C. (1970). Treatment of Parkinsonism with Laevodopa. Br. Med. J, 1, 331
Jenkins, R. B. and Groh, R. H. (1970). Mental symptoms in Parkinsonian patients treated with L-dopa. Lancet, ii, 177
Godwin-Austen, R. B., Bergmann, S. and Frears, C. C. (1971b). Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa. Br. Med. J, 4, 522
God win-Austen, R. B., Frears, C. C. and Bergmann, S. (1971a). Incidence of side-effects from levodopa during the introduction of treatment. Br. Med. J, 1, 267
Peaston, M. J. T. and Bianchine, J. R. (1970). Metabolic studies and clinical observations during L-dopa treatment of Parkinson’s disease. Br. Med. J, 1, 400
Leader (1978). Drugs for Parkinson’s disease. Lancet, i, 754
Sutcliffe, R. L. G. (1973). L-dopa therapy in elderly patients with Parkinsonism. Age Ageing, 2, 34
Vignalou, J. and Beck, H. (1973). La L-dopa chez 122 Parkinsoniens de plus de 70 ans. Gerontol. Clin, 15, 50
Hildick-Smith, M. (1973). The patient’s view of L-dopa after one year’s therapy. Gerontol. Clin, 15, 74
Hildick-Smith, M. (1973). Pyridoxine in Parkinsonism. Lancet, ii, 1029
Hunter, K. R., Hollman, A., Laurence, D. R. and Stern, G. M. (1971), Levodopa in Parkinsonian patients with heart disease. Lancet, i, 932
Marsden, C. D., Parkes, J. D. and Rees, J. E. (1973). A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet, ii, 1459
Cotzias, G. C., Papavasiliou, P. S. and Gellene, R. (1969). Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med, 280, 337
Diamond, S. G., Markham, C. H. and Treciokas, L. J. (1978). A double-blind comparison of Levodopa, Madopa and Sinfcmet in Parkinson’s Disease. Ann. Neurol, 3, 267
Korten, J. J., Keyser, A., Joosten, M. G. and Gabreels, F. J. M. (1975). Madopar versus Sinemet. Eur. Neurol, 13, 65
Martin, W. E., Toloso, E. S., Loewenson, R. B., Lee, M. C., Resch, J. A. and Baker, A. B. (1976). Safer drug treatment for patients with Parkinson’s disease. Mod. Geriatr, 6, (no. 2) 11
Marsden, C. D., Barry, P. E., Parkes, J. D. and Zilkha, K. J. (1973). Treatment of Parkinson’s disease with levodopa combined with L-alpha- methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J. Neurol. Neurosurg. Psychiatry, 36, 10
Critchley, E. (1975). L-dopa and carbidopa (sinemet) in the management of Parkinsonism. Postgrad. Med. J, 51, 619
Mars, H. and Krall, J. (1971). L-dopa and cardiac arrhythmias. N. Engl J. Med, 285, 1437
Calne, D. B, Petrie, A., Rao, S., Reid, J. L. and Vakil, S. D. (1972). Action of L-alpha-methyldopahydrazine on the blood pressure of patients receiving levodopa. Br. J. Pharmacol, 44, 162
Klawans, H. L., Ringel, S. P. and Shenker, D. M. (1971). Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor. J. Neurol Neurosurg. Psychiatry, 34, 682
Barbeau, A., Mars, H., Botez, M. I. and Joubert, M. (1972). Levodopa combined with peripheral decarboxylase inhibition in Parkinson’s disease. Canad. Med. Assoc. J, 106, 1169
Hildick-Smith, M. (1976). Alternatives to levodopa. Br. Med. J, 1, 1406
Hunter, K. R, Laurence, D. R, Shaw, K. M. and Stern, G. M. (1973). Sustained levodopa therapy in Parkinsonism. Lancet, ii, 929
Barbeau, A. (1976). Six years of high-level levodopa therapy in severely akinetic Parkinsonian patients. Arch. Neurol, 33, 333
Sweet, R. D., and McDowell, F. (1974). The on — off response to chronic L-dopa treatment of Parkinsonism. In McDowell, F. H. and Barbeau, A. (eds.). Advances in Neurology, 5, p. 331. ( New York: Raven Press )
Marsden, C. D. and Parkes, J. D. (1976). On — off effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet, i, 292
Yahr, M. D. (1977). Longterm levodopa in Parkinson’s disease. Lancet, i, 706
Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastmann, R., Greenacre, J. K. and Petrie, A. (1974). Bromocriptine in Parkinsonism. Br. Med. J, 4, 442
Kartzinel, R., Teychenne, P., Gillespie, M. M., Perlow, M., Gielen, A. C., Sadowsky, D. A. and Calne, D. B. (1976). Bromocriptine and levodopa (with or without carbidopa) in Parkinsonism. Lancet, ii, 272
Parkes, J. D., Debono, A. G. and Marsden, C. D. (1976). Bromocriptine in Parkinsonism: longterm treatment, dose response and comparison with levodopa. J. Neurol Neurosurg. Psychiatry, 39, 1101
Marsden, C. D. and Parkes, J. D. (1976). Bromocriptine in Parkinsonism. Lancet, ii, 419
Wass, J. A. H., Thorner, M. O. and Besser, G. M. (1976). Digital vasospasm with bromocriptine. Lancet, i, 1135
Calne, D. B., Plotkin, C., Williams, A. C., Nutt, J. G., Neophytides, A. and Teychenne, P. F. (1978). Longterm treatment of Parkinsonism with bromocriptine. Lancet, i, 735
Bédard, P., Parkes, J. D. and Marsden, C. D. (1978). Effect of new dopamine- blocking agent (oxiperomide) in drug-induced dyskinesias in Parkinson’s disease and spontaneous dyskinesias. Br. Med. J, 1, 954
Birkmayer, W. (1976). Medical treatment of Parkinson’s disease: General review, past and present. In Birkmayer, W. and Hornykiewicz, O. (eds). Advances in Parkinsonism, pp. 407–424 ( Basle: Roche )
Quaglieri, C. E. and Celesia, G. G. (1977). Effect of thalamotomy and L-dopa therapy on the speech of Parkinsonian patients. Eur. Neurol, 15, 34
Selby, G. (1976). The influence of previous stereotactic thalamotomy on L-dopa treatment in Parkinson’s disease. Proc. Aust. Assoc. Neurol, 13, 55
Greer, M. (1976). How to achieve maximum benefit for the patient with Parkinson’s disease. Geriatrics, 31, 89
Rampton, D. S. (1977). Hypertensive crisis in a patient given sinemet, metoclo- pramide and amitryptiline. Br. Med. J, 2, 607
Hausner, R. (1976). Drugs that reduce efficacy of levodopa. N. Engl. J. Med, 295, 1538
Ball, B. (1882). De l’insanité dans la paralysie agitante. Encephale, 2, 22
Loranger, A. W, Goodell, H., McDowell, F. H., Lee, J. E., and Sweet, R. D. (1972). Intellectual impairment in Parkinson’s syndrome. Brain, 95, 405
Celesia, G. C. and Wannamaker, W. M. (1972). Psychiatric disturbances in Parkinson’s disease. Dis. Nerv. Syst, 33, 577
Eadie, M. J. and Sutherland, J. M. (1964). Arteriosclerosis in Parkinsonism. J. Neurol. Neurosurg. Psychiatry, 27, 237
Pearce, J. (1974). Mental changes in Parkinsonism. Br. Med. J, 2, 445
Sacks, O. W., Messeloff, C, Schartz, W, Goldfarb, A. and Kohl, M. (1970). Effects of L-dopa in patients with dementia. Lancet, i, 1231
Wolf, S. M. and Davis, R. L. (1973). Permanent dementia in idiopathic Parkinsonism treated with levodopa. Arch. Neurol, 29, 276
Drachman, D. A. and Stahl (1975). Extrapyramidal dementia and levodopa. Lancet, i, 809
Pollock, M. and Hornabrook, R. W. (1966). The prevalence, natural history and dementia of Parkinsonism. Brain, 89, 429
Davis, J. C. (1977). Team management of Parkinson’s disease. Am. J. Occup. Ther, 31, (no. 5)-300
Hurwitz, L. J. (1964). Improving mobility in severely disabled Parkinsonian patients. Lancet, ii, 953
Singer, E. (1973). Social costs of Parkinson’s disease. J. Chron. Dis, 26, 243
God win-Austen, R. B. (1971). Parkinson’s Disease. A booklet for patients and their families, published and distributed by the Parkinson’s Disease Society, 81 Queen’s Road, London
Parkinson’s Disease Day to Day. A further booklet published by the Parkinson’s Disease Society, London
Reviews
Jewesbury, E. C. O. (1970). Parkinsonism. Br. J. Hosp. Med, 4, 825
Leader (1974). Mental changes in Parkinsonism. Br. Med. J, 2, 1
Bianchine, J. R. and Sunyapridakul L. (1974). Individualisation of levodopa therapy. Med. Clin. N. Am, 58, 1071
Davison, W. (1974). Management of Parkinsonism. Mod. Geriatr 4, 102
Hornekiewicz, O. (1975). Parkinson’s disease and its chemotherapy. Biochem. Pharmacol, 24, 1061
Barbeau, A. (1975). Longterm assessment of levodopa therapy in Parkinson’s disease. Canad. Med. Assoc. J, 112, 1379
Yahr, M. D. (1975). Levodopa. Ann. Intern. Med, 83, 677
Calne, D. B. (1976). Developments in the treatment of Parkinsonism. N. Engl. J. Med, 295, 1433
Bianchine. J. (1976). Drug therapy of Parkinsonism. N. Engl. J. Med, 295, 814
Leader (1976). Alternatives to levodopa. Br. Med. J, 1, 1169
Curzon, G. (1977). The biochemistry of the basal ganglia and Parkinson’s disease. Postgrad. Med. J, 53, 719
Godwin-Austen, R. B. (1977). The treatment of Parkinson’s disease. Postgrad. Med. J, 53, 729
Marsden, C. D. and Parkes, J. D. (1977). Success and problems of longterm levodopa therapy in Parkinson’s disease. Lancet, i, 345
Duvoisin, R. C. (1977). Problems in the treatment of Parkinsonism. In Messiha, F. S. and Kenny, A. D. (eds.). Parkinson’s Disease, pp. 131–149. ( New York and London: Plenum Press )
Stern, G. M. and Lees, A. J. (1978). Choice of treatments in Parkinson’s disease. Practitioner, 219, 537
Pearce, I, and Pearce, J. M. S. (1978). Bromocriptine in Parkinsonism. Br. Med. J, 1, 1402
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 MTP Press Limited
About this chapter
Cite this chapter
Hildick-Smith, M. (1980). Management of Parkinson’s disease in the elderly. In: Denham, M.J. (eds) The Treatment of Medical Problems in the Elderly. Current Status of Modern Therapy, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-6223-4_6
Download citation
DOI: https://doi.org/10.1007/978-94-011-6223-4_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-011-6225-8
Online ISBN: 978-94-011-6223-4
eBook Packages: Springer Book Archive